Business Summary (taken yahoo) Antigenics, Inc. is developing treatments for cancers, serious infectious diseases, autoimmune disorders and degenerative disorders, using the Company's proprietary technologies to program the immune system and improve quality of life. These products include immunotherapeutics based on a specific class of heat shock proteins (HSPs), which activate powerful cellular immune responses, and Stimulon-based products, including QS-21, which activates superior antibody responses. At year-end 2000, the Company was evaluating its lead HSP-based immunotherapeutic, Oncophage, in an international multi-center Phase III clinical trial in kidney cancer, and in five additional cancer indications in Phase II or Phase I/II trials. Through its internal programs and partnerships, the Company was also testing its Stimulon-based products in 11 Phase III and Phase II clinical trials for cancer, several infectious diseases and degenerative disorders.
Sara
Sara
"I never give them hell. I just tell the truth and they think it's hell." - Harry Truman
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.